Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7981204 | 0.78 | CTNNB1 (0.60) | L3MBTL1RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL6203131 | 0.76 | CYP2C19 (0.66) | RAB9ANPC1POLBALDH1A1CYP2C19 | |
| SCHEMBL1255851 | 0.74 | ALDH1A1 (0.62) | L3MBTL1RAB9ANPC1POLBALDH1A1 | |
| SCHEMBL2722463 | 0.74 | ALDH1A1 (0.48) | L3MBTL1RAB9ANPC1POLBALDH1A1 | |
| SCHEMBL2722560 | 0.73 | SMN1; SMN2 (0.45) | L3MBTL1RAB9ANPC1POLBALDH1A1 | |
| SCHEMBL10924969 | 0.73 | PKM (0.57) | L3MBTL1RAB9ANPC1KDM4EMAPT | |
| SCHEMBL17985011 | 0.73 | KDM4E (0.60) | RAB9ANPC1POLBALDH1A1KDM4E | |
| SCHEMBL2724156 | 0.72 | ALDH1A1 (0.56) | POLBALDH1A1MAPTCYP2C19GAA | |
| SCHEMBL6474309 | 0.72 | ALDH1A1 (0.56) | L3MBTL1RAB9ANPC1POLBALDH1A1 | |
| SCHEMBL3452522 | 0.72 | RAB9A (0.62) | RAB9ANPC1POLBALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133178-B2 | Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer'S disease | PROXIMAGEN LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-9133178-B2 | Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer'S disease | PROXIMAGEN LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-9133178-B2 | Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer'S disease | PROXIMAGEN LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20130310380-A1 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE | PROXIMAGEN LIMITED (GB) | 2013-11-21 | — | — | US | disclosed |
| US-20130310380-A1 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE | PROXIMAGEN LIMITED (GB) | 2013-11-21 | — | — | US | disclosed |
| EP-2632918-A1 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE | Proximagen Limited (GB) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012055942-A1 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE | PROXIMAGEN LIMITED (GB) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012055942-A1 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE | PROXIMAGEN LIMITED (GB) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310380-A1 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE | CHRNA7, CHRNA10, CHRNA5 | L3MBTL1 3485/4885RAB9A 1548/4885NPC1 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.